These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

412 related articles for article (PubMed ID: 21699492)

  • 1. Strategies on the development of small molecule anticancer drugs for targeted therapy.
    Lu YH; Gao XQ; Wu M; Zhang-Negrerie D; Gao Q
    Mini Rev Med Chem; 2011 Jun; 11(7):611-24. PubMed ID: 21699492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prodrugs in combination with nanocarriers as a strategy for promoting antitumoral efficiency.
    Lin MH; Hung CF; Hsu CY; Lin ZC; Fang JY
    Future Med Chem; 2019 Aug; 11(16):2131-2150. PubMed ID: 31538520
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current prodrug design for drug discovery.
    Hsieh PW; Hung CF; Fang JY
    Curr Pharm Des; 2009; 15(19):2236-50. PubMed ID: 19601825
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting drug delivery system for platinum(Ⅳ)-Based antitumor complexes.
    Zhong Y; Jia C; Zhang X; Liao X; Yang B; Cong Y; Pu S; Gao C
    Eur J Med Chem; 2020 May; 194():112229. PubMed ID: 32222677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anticancer boron-containing prodrugs responsive to oxidative stress from the tumor microenvironment.
    Maslah H; Skarbek C; Pethe S; Labruère R
    Eur J Med Chem; 2020 Dec; 207():112670. PubMed ID: 32858470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anticancer platinum (IV) prodrugs with novel modes of activity.
    Chin CF; Wong DY; Jothibasu R; Ang WH
    Curr Top Med Chem; 2011; 11(21):2602-12. PubMed ID: 22039869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prodrug applications for targeted cancer therapy.
    Giang I; Boland EL; Poon GM
    AAPS J; 2014 Sep; 16(5):899-913. PubMed ID: 25004822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anticancer metallodrugs: where is the next cisplatin?
    Hanif M; Hartinger CG
    Future Med Chem; 2018 Mar; 10(6):615-617. PubMed ID: 29411994
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypoxia-targeted drug delivery.
    Sharma A; Arambula JF; Koo S; Kumar R; Singh H; Sessler JL; Kim JS
    Chem Soc Rev; 2019 Feb; 48(3):771-813. PubMed ID: 30575832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anticancer prodrugs: an overview of major strategies and recent developments.
    Arpicco S; Dosio F; Stella B; Cattel L
    Curr Top Med Chem; 2011; 11(18):2346-81. PubMed ID: 21671864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Small Molecule Inhibitors of HSF1-Activated Pathways as Potential Next-Generation Anticancer Therapeutics.
    Sharma C; Seo YH
    Molecules; 2018 Oct; 23(11):. PubMed ID: 30356024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance.
    Shapira A; Livney YD; Broxterman HJ; Assaraf YG
    Drug Resist Updat; 2011 Jun; 14(3):150-63. PubMed ID: 21330184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent trends in targeted anticancer prodrug and conjugate design.
    Singh Y; Palombo M; Sinko PJ
    Curr Med Chem; 2008; 15(18):1802-26. PubMed ID: 18691040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prodrug strategy for cancer cell-specific targeting: A recent overview.
    Zhang X; Li X; You Q; Zhang X
    Eur J Med Chem; 2017 Oct; 139():542-563. PubMed ID: 28837920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ROS-activated anticancer prodrugs: a new strategy for tumor-specific damage.
    Peng X; Gandhi V
    Ther Deliv; 2012 Jul; 3(7):823-33. PubMed ID: 22900465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prodrug-based nanoparticulate drug delivery strategies for cancer therapy.
    Luo C; Sun J; Sun B; He Z
    Trends Pharmacol Sci; 2014 Nov; 35(11):556-66. PubMed ID: 25441774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Self-assembly drug conjugates for anticancer treatment.
    Fumagalli G; Marucci C; Christodoulou MS; Stella B; Dosio F; Passarella D
    Drug Discov Today; 2016 Aug; 21(8):1321-9. PubMed ID: 27329268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypoxia Responsive Drug Delivery Systems in Tumor Therapy.
    Alimoradi H; Matikonda SS; Gamble AB; Giles GI; Greish K
    Curr Pharm Des; 2016; 22(19):2808-20. PubMed ID: 26898739
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Somatostatin receptor-mediated specific delivery of paclitaxel prodrugs for efficient cancer therapy.
    Huo M; Zhu Q; Wu Q; Yin T; Wang L; Yin L; Zhou J
    J Pharm Sci; 2015 Jun; 104(6):2018-2028. PubMed ID: 25820241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A safe, simple and efficient doxorubicin prodrug hybrid micelle for overcoming tumor multidrug resistance and targeting delivery.
    Bao Y; Yin M; Hu X; Zhuang X; Sun Y; Guo Y; Tan S; Zhang Z
    J Control Release; 2016 Aug; 235():182-194. PubMed ID: 27264552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.